{"kind":"expression","expression":{"expr_id":"1307","doc_id":"1307","label":"SL 72 of 2021","is_as_enacted":"t","commenced_on":null,"superseded_on":null,"valid_from":null,"valid_to":null,"is_current":"t","incorporating":null,"akn_expr_iri":"\/akn\/ky\/act\/sl\/2021\/72\/eng@2021-01-01","akn_envelope":"{\"_canary\": {\"iri\": {\"work\": \"\/akn\/ky\/act\/sl\/2021\/72\", \"expression\": \"\/akn\/ky\/act\/sl\/2021\/72\/eng@2021-01-01\", \"manifestation\": \"\/akn\/ky\/act\/sl\/2021\/72\/eng@2021-01-01.pdf\"}, \"pdf\": {\"md5\": \"474bb35c7a217ed41213b42bd5d97946\", \"path\": \"\/Users\/q\/kyleg-data\/working\/SUBORDINATE\/2021\/2021-0072\/2021-0072_SL 72 of 2021.pdf\", \"pages\": 8, \"filename\": \"2021-0072_SL 72 of 2021.pdf\"}, \"errors\": [], \"extraction\": {\"model\": null, \"stats\": {\"word_count\": 1301, \"paragraph_count\": 7, \"text_char_count\": 8628}, \"usage\": null, \"method\": \"pymupdf-text\", \"version\": \"kyleg-akn-1.0\", \"extracted_at\": \"2026-06-22\"}, \"classification\": \"text_layer\", \"validation_flags\": [], \"docai_processor_id\": null}, \"akomaNtoso\": {\"act\": {\"body\": [{\"eId\": \"sec_n1\", \"num\": null, \"text\": \"Public Health Act (2021 Revision) CONTROL OF COVID-19 (TESTING) REGULATIONS, 2021 (SL 72 of 2021) SL 72 of 2021 PUBLISHING DETAILS Arrangement of Regulations SL 72 of 2021 Public Health Act (2021 Revision) CONTROL OF COVID-19 (TESTING) REGULATIONS, 2021 (SL 72 of 2021) Arrangement of Regulations Regulation 1. 2. 3. 4. 5.\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_6\", \"num\": \"6.\", \"text\": \"Regulation 1 SL 72 of 2021 Public Health Act (2021 Revision) CONTROL OF COVID-19 (TESTING) REGULATIONS, 2021 (SL 72 of 2021) In exercise of the powers conferred by section 34 of the Public Health Act (2021 Revision), the Cabinet makes the following Regulations \u2014\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_1\", \"num\": \"1.\", \"text\": \"Citation 1. These Regulations may be cited as the Control of Covid-19 (Testing) Regulations, 2021.\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_2\", \"num\": \"2.\", \"text\": \"Definitions 2. In these Regulations \u2014 \u201cCayman Islands Health Services Authority\u201d means the Cayman Islands Health Services Authority established under section 3 of the Health Services Authority Act (2018 Revision); \u201chealth care facility\u201d means premises at which health services are provided by a registered practitioner and in respect of which a certificate is issued under section 5 of the Health Practice Act (2021 Revision); \u201chealth services\u201d include clinical examination, nursing care, dental care, the provision of blood and blood products, diagnostic procedures, the provision of medical and surgical services, the provision of pharmaceuticals, advice or Regulation 3 SL 72 of 2021 counselling and any other service as is provided by a registered practitioner under the Health Practice Act (2021 Revision); \u201cmanager\u201d, in relation to a health care facility or a medical tourism facility, includes the owner; \u201cmedical tourism facility\u201d means a health care facility designated by the Cabinet under section 7A(2) of the Health Practice Act (2021 Revision); \u201cmolecular testing\u201d includes polymerase chain reaction testing; \u201cregistered practitioner\u201d means any person qualified to practise any of the professions specified in the Health Practice Act (2021 Revision) and registered under the Health Practice Act (2021 Revision); and \u201cvirus\u201d means the virus known as SARS-CoV-2 which causes the disease known as Covid-19.\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_3\", \"num\": \"3.\", \"text\": \"Conditions for the provision of molecular testing services for the virus 3. (1) For the purpose of the control of the virus in the Islands, molecular testing services may only be provided by a registered practitioner, a health care facility or a medical tourism facility that receives the written approval of the Medical Officer of Health under paragraph (2) or (5). (2) Where the Medical Officer of Health notifies, by way of a notice published in the Gazette, in any other official Government website or in any other official means of communication, that there is a need for increased molecular testing capacity, a registered practitioner, a manager of a health care facility or a manager of a medical tourism facility who satisfies the requirements in paragraph (3), may apply in writing to the Medical Officer of Health to provide molecular testing services and the Medical Officer of Health shall provide written approval of the application. (3) The requirements referred to in paragraph (2) are that the relevant laboratory is one that \u2014 (a) is accredited by the Joint Commission International (JCI) or the International Organization for Standardization (ISO) or a similar accrediting organization; or (b) has reached an acceptable standard in the detection of the virus as determined by the United Kingdom\u2019s Health Security Agency or the Pan American Health Organization, and has had its test results validated by the laboratory at the Cayman Islands Health Services Authority. (4) A registered practitioner, a manager of a health care facility or a manager of a medical tourism facility who is approved under paragraph (2) or (5) to provide molecular testing services shall report to the Medical Officer of Health, in such form as the Medical Officer of Health may specify, the result of any test for the Regulation 4 SL 72 of 2021 virus conducted by way of molecular testing no later than twelve hours after receiving the result and the report shall include in relation to the person on whom the test was administered \u2014 (a) the full name; (b) the date of birth; (c) the sex; (d) the telephone number; (e) the email address; (f) the home address; (g) the place of work; and (h) any other relevant information which the Medical Officer of Health may request. (5) Any registered practitioner, manager of a health care facility or manager of a medical tourism facility who on the day immediately preceding the coming into force of these Regulations had received written approval from the Medical Officer of Health for the purpose of providing molecular testing for the virus is exempt from the requirement to apply for approval under this regulation and that prior approval shall be considered as an approval under paragraph (2). (6) Notwithstanding paragraph (5), a registered practitioner, a manager of a health care facility or a manager of a medical tourism facility who is exempt from the requirement to apply for approval under paragraph (2) shall comply in every other respect with these Regulations. (7) The approval granted to a registered practitioner, a manager of a health care facility or a manager of a medical tourism facility under paragraph (2) or (5) may be revoked where the Medical Officer of Health determines that there is failure to comply with the reporting requirements under paragraph (4).\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_4\", \"num\": \"4.\", \"text\": \"Conditions for the supply of antigen-detecting rapid diagnostic tests 4. (1) Subject to paragraph (2), a person who, for the purpose of the control of the virus, imports into or supplies in the Islands antigen-detecting rapid diagnostic tests shall ensure that the tests are either \u2014 (a) the antigen-detecting rapid diagnostic tests \u2014 (i) which have a sensitivity of at least 80 per cent and a specificity of at least 97 per cent; and (ii) which are recommended or approved for use by a national public health agency of the United States of America, the United Kingdom, the European Union, Australia, New Zealand, Jamaica or Canada following rigorous testing and for which there is documentary evidence of this recommendation or approval; or Regulation 5 SL 72 of 2021 (b) the antigen-detecting rapid diagnostic tests which are approved for use by the Medical Officer of Health and specified in a notice published by the Medical Officer of Health in the Gazette, in any other official Government website or in any other official means of communication. (2) An antigen-detecting rapid diagnostic test under paragraph (1) may be supplied to the public for personal use, except where the antigen-detecting rapid diagnostic test is specified as being for clinical use only.\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_5\", \"num\": \"5.\", \"text\": \"Offence and Penalty 5. A person who \u2014 (a) provides molecular testing services in contravention of regulation 3; or (b) imports or supplies antigen-detecting rapid diagnostic tests in contravention of regulation 4, commits an offence and is liable on summary conviction to a fine of ten thousand dollars or to imprisonment for a term of two years, or to both. 6. Expiry 6. These Regulations cease to have effect at the end of the period of one year beginning on the day on which they come into force or at such other date as may be specified by Cabinet by notice published in the Gazette. Made in Cabinet the 15th day of October, 2021. Kim Bullings Clerk of the Cabinet\", \"element\": \"section\", \"heading\": null}], \"meta\": {\"notes\": null, \"workflow\": null, \"lifecycle\": {\"source\": \"#cilegis\", \"eventRef\": [{\"eId\": \"e_commence_2021_01_01\", \"date\": \"2021-01-01\", \"type\": \"generation\", \"source\": \"#cilegis\"}]}, \"references\": {\"source\": \"#canary\", \"TLCRole\": [], \"TLCEvent\": [{\"eId\": \"ev_commencement\", \"href\": \"\/akn\/ontology\/canary\/event\/commencement\", \"showAs\": \"commencement\"}], \"TLCPerson\": [], \"TLCConcept\": [{\"eId\": \"inForce\", \"href\": \"\/akn\/ontology\/canary\/concept\/temporal\/in-force\", \"showAs\": \"in force\"}], \"TLCProcess\": [], \"TLCLocation\": [], \"TLCOrganization\": [{\"eId\": \"cilegis\", \"href\": \"\/akn\/ontology\/canary\/organization\/editor\/cilegis\", \"showAs\": \"Cayman Islands legislation mirror (kyleg)\"}]}, \"temporalData\": {\"source\": \"#cilegis\", \"temporalGroup\": [{\"eId\": \"tg_inforce_2021_01_01\", \"timeInterval\": [{\"end\": null, \"start\": \"#e_commence_2021_01_01\", \"duration\": null, \"refersTo\": \"#inForce\"}]}]}, \"classification\": null, \"identification\": {\"source\": \"#cilegis\", \"FRBRWork\": {\"FRBRuri\": \"\/akn\/ky\/act\/sl\/2021\/72\", \"FRBRdate\": [{\"date\": \"2021-01-01\", \"name\": \"generation\"}], \"FRBRthis\": \"\/akn\/ky\/act\/sl\/2021\/72\/!main\", \"FRBRalias\": [{\"name\": \"cmsId\", \"value\": \"2021-0072\"}], \"FRBRauthor\": [{\"as\": \"#editor\", \"href\": \"\/akn\/ontology\/canary\/organization\/editor\/cilegis\"}], \"FRBRnumber\": \"72 of 2021\", \"FRBRcountry\": \"ky\", \"FRBRsubtype\": \"subordinate\"}, \"FRBRExpression\": {\"FRBRuri\": \"\/akn\/ky\/act\/sl\/2021\/72\/eng@2021-01-01\", \"FRBRdate\": [{\"date\": \"2021-01-01\", \"name\": \"generation\"}], \"FRBRthis\": \"\/akn\/ky\/act\/sl\/2021\/72\/eng@2021-01-01\/!main\", \"FRBRauthor\": [{\"as\": \"#editor\", \"href\": \"\/akn\/ontology\/canary\/organization\/editor\/cilegis\"}], \"FRBRlanguage\": \"eng\"}, \"FRBRManifestation\": {\"FRBRuri\": \"\/akn\/ky\/act\/sl\/2021\/72\/eng@2021-01-01.xml\", \"FRBRdate\": [{\"date\": \"2026-06-22\", \"name\": \"generation\"}], \"FRBRthis\": \"\/akn\/ky\/act\/sl\/2021\/72\/eng@2021-01-01.xml\", \"FRBRauthor\": [{\"as\": \"#editor\", \"href\": \"\/akn\/ontology\/canary\/organization\/editor\/cilegis\"}], \"FRBRformat\": \"application\/xml\"}}}, \"name\": \"act\", \"header\": {\"title\": \"Control of Covid-19 (Testing) Regulations, 2021\", \"actNumber\": \"72 of 2021\", \"longTitle\": null}}, \"doc\": null, \"bill\": null, \"judgment\": null}}","akn_full_text":"CAYMAN ISLANDS\n\nPublic Health Act\n(2021 Revision)\nCONTROL OF COVID-19 (TESTING)\nREGULATIONS, 2021\n(SL 72 of 2021)\nSupplement No. 1 published with Legislation Gazette No. 57 dated 15th October, 2021.\n\u2000\n\nPage 2\nSL 72 of 2021\nc\n\nPUBLISHING DETAILS\n\nControl of Covid-19 (Testing) Regulations, 2021\nArrangement of Regulations\n\nc\nSL 72 of 2021\nPage 3\n\nCAYMAN ISLANDS\n\nPublic Health Act\n(2021 Revision)\nCONTROL OF COVID-19 (TESTING)\nREGULATIONS, 2021\n(SL 72 of 2021)\nArrangement of Regulations\nRegulation\nPage\n1.\nCitation ......................................................................................................................................5\n2.\nDefinitions ..................................................................................................................................5\n3.\nConditions for the provision of molecular testing services for the virus .......................................6\n4.\nConditions for the supply of antigen-detecting rapid diagnostic tests ..........................................7\n5.\nOffence and Penalty ..................................................................................................................8\n6.\nExpiry ........................................................................................................................................8\n\nControl of Covid-19 (Testing) Regulations, 2021\nRegulation 1\n\nc\nSL 72 of 2021\nPage 5\n\nCAYMAN ISLANDS\n\nPublic Health Act\n(2021 Revision)\nCONTROL OF COVID-19 (TESTING)\nREGULATIONS, 2021\n(SL 72 of 2021)\nIn exercise of the powers conferred by section 34 of the Public Health Act (2021 Revision),\nthe Cabinet makes the following Regulations \u2014\n1.\nCitation\n1.\nThese Regulations may be cited as the Control of Covid-19 (Testing) Regulations,\n2021.\n2.\nDefinitions\n2.\nIn these Regulations \u2014\n\u201cCayman Islands Health Services Authority\u201d means the Cayman Islands\nHealth Services Authority established under section 3 of the Health Services\nAuthority Act (2018 Revision);\n\u201chealth care facility\u201d means premises at which health services are provided by\na registered practitioner and in respect of which a certificate is issued under\nsection 5 of the Health Practice Act (2021 Revision);\n\u201chealth services\u201d include clinical examination, nursing care, dental care, the\nprovision of blood and blood products, diagnostic procedures, the provision of\nmedical and surgical services, the provision of pharmaceuticals, advice or\n\nRegulation 3\nControl of Covid-19 (Testing) Regulations, 2021\n\nPage 6\nSL 72 of 2021\nc\n\ncounselling and any other service as is provided by a registered practitioner\nunder the Health Practice Act (2021 Revision);\n\u201cmanager\u201d, in relation to a health care facility or a medical tourism facility,\nincludes the owner;\n\u201cmedical tourism facility\u201d means a health care facility designated by the\nCabinet under section 7A(2) of the Health Practice Act (2021 Revision);\n\u201cmolecular testing\u201d includes polymerase chain reaction testing;\n\u201cregistered practitioner\u201d means any person qualified to practise any of the\nprofessions specified in the Health Practice Act (2021 Revision) and registered\nunder the Health Practice Act (2021 Revision); and\n\u201cvirus\u201d means the virus known as SARS-CoV-2 which causes the disease\nknown as Covid-19.\n3.\nConditions for the provision of molecular testing services for the virus\n3.\n(1) For the purpose of the control of the virus in the Islands, molecular testing\nservices may only be provided by a registered practitioner, a health care facility\nor a medical tourism facility that receives the written approval of the Medical\nOfficer of Health under paragraph (2) or (5).\n(2) Where the Medical Officer of Health notifies, by way of a notice published in\nthe Gazette, in any other official Government website or in any other official\nmeans of communication, that there is a need for increased molecular testing\ncapacity, a registered practitioner, a manager of a health care facility or a\nmanager of a medical tourism facility who satisfies the requirements in\nparagraph (3), may apply in writing to the Medical Officer of Health to provide\nmolecular testing services and the Medical Officer of Health shall provide\nwritten approval of the application.\n(3) The requirements referred to in paragraph (2) are that the relevant laboratory is\none that \u2014\n(a)\nis accredited by the Joint Commission International (JCI) or the\nInternational Organization for Standardization (ISO) or a similar\naccrediting organization; or\n(b) has reached an acceptable standard in the detection of the virus as\ndetermined by the United Kingdom\u2019s Health Security Agency or the Pan\nAmerican Health Organization,\nand has had its test results validated by the laboratory at the Cayman Islands\nHealth Services Authority.\n(4) A registered practitioner, a manager of a health care facility or a manager of a\nmedical tourism facility who is approved under paragraph (2) or (5) to provide\nmolecular testing services shall report to the Medical Officer of Health, in such\nform as the Medical Officer of Health may specify, the result of any test for the\n\nControl of Covid-19 (Testing) Regulations, 2021\nRegulation 4\n\nc\nSL 72 of 2021\nPage 7\n\nvirus conducted by way of molecular testing no later than twelve hours after\nreceiving the result and the report shall include in relation to the person on whom\nthe test was administered \u2014\n(a)\nthe full name;\n(b) the date of birth;\n(c)\nthe sex;\n(d) the telephone number;\n(e)\nthe email address;\n(f)\nthe home address;\n(g) the place of work; and\n(h) any other relevant information which the Medical Officer of Health may\nrequest.\n(5) Any registered practitioner, manager of a health care facility or manager of a\nmedical tourism facility who on the day immediately preceding the coming into\nforce of these Regulations had received written approval from the Medical\nOfficer of Health for the purpose of providing molecular testing for the virus is\nexempt from the requirement to apply for approval under this regulation and\nthat prior approval shall be considered as an approval under paragraph (2).\n(6) Notwithstanding paragraph (5), a registered practitioner, a manager of a health\ncare facility or a manager of a medical tourism facility who is exempt from the\nrequirement to apply for approval under paragraph (2) shall comply in every\nother respect with these Regulations.\n(7) The approval granted to a registered practitioner, a manager of a health care\nfacility or a manager of a medical tourism facility under paragraph (2) or (5)\nmay be revoked where the Medical Officer of Health determines that there is\nfailure to comply with the reporting requirements under paragraph (4).\n4.\nConditions for the supply of antigen-detecting rapid diagnostic tests\n4.\n(1) Subject to paragraph (2), a person who, for the purpose of the control of the\nvirus, imports into or supplies in the Islands antigen-detecting rapid diagnostic\ntests shall ensure that the tests are either \u2014\n(a)\nthe antigen-detecting rapid diagnostic tests \u2014\n(i)\nwhich have a sensitivity of at least 80 per cent and a specificity of at\nleast 97 per cent; and\n(ii) which are recommended or approved for use by a national public\nhealth agency of the United States of America, the United Kingdom,\nthe European Union, Australia, New Zealand, Jamaica or Canada\nfollowing rigorous testing and for which there is documentary\nevidence of this recommendation or approval; or\n\nRegulation 5\nControl of Covid-19 (Testing) Regulations, 2021\n\nPage 8\nSL 72 of 2021\nc\n\n(b) the antigen-detecting rapid diagnostic tests which are approved for use by\nthe Medical Officer of Health and specified in a notice published by the\nMedical Officer of Health in the Gazette, in any other official Government\nwebsite or in any other official means of communication.\n(2) An antigen-detecting rapid diagnostic test under paragraph (1) may be supplied\nto the public for personal use, except where the antigen-detecting rapid\ndiagnostic test is specified as being for clinical use only.\n5.\nOffence and Penalty\n5.\nA person who \u2014\n(a)\nprovides molecular testing services in contravention of regulation 3; or\n(b) imports or supplies antigen-detecting rapid diagnostic tests in\ncontravention of regulation 4,\ncommits an offence and is liable on summary conviction to a fine of ten thousand\ndollars or to imprisonment for a term of two years, or to both.\n6.\nExpiry\n6.\nThese Regulations cease to have effect at the end of the period of one year beginning\non the day on which they come into force or at such other date as may be specified\nby Cabinet by notice published in the Gazette.\nMade in Cabinet the 15th day of October, 2021.\nKim Bullings\nClerk of the Cabinet","akn_extracted_at":"2026-06-22 15:38:16.890289+00","cms_id":"2021-0072","law_type":"subordinate","year":"2021","number":"72","title":"Control of Covid-19 (Testing) Regulations, 2021","status":"revoked"},"provenance":{"files":[{"file_id":"6160","expr_id":"1307","kind":"akn_xml","filename":"2021-0072_SL 72 of 2021.akn.xml","source_url":null,"storage_path":"\/Users\/q\/kyleg-data\/working\/SUBORDINATE\/2021\/2021-0072\/2021-0072_SL 72 of 2021.akn.xml","content_md5":"e80013a83c1ebb44c3e3ccc620226779","byte_size":"10724","http_last_modified":null,"fetched_at":"2026-06-22 15:38:16.960079+00"},{"file_id":"2613","expr_id":"1307","kind":"pristine_pdf","filename":"2021-0072_SL 72 of 2021.pdf","source_url":"\/cms\/images\/LEGISLATION\/SUBORDINATE\/2021\/2021-0072\/2021-0072_SL 72 of 2021.pdf","storage_path":"\/Users\/q\/kyleg-data\/pristine\/SUBORDINATE\/2021\/2021-0072\/2021-0072_SL 72 of 2021.pdf","content_md5":"474bb35c7a217ed41213b42bd5d97946","byte_size":"761168","http_last_modified":null,"fetched_at":"2026-06-16 04:01:10.692772+00"},{"file_id":"2614","expr_id":"1307","kind":"working_pdf","filename":"2021-0072_SL 72 of 2021.pdf","source_url":"\/cms\/images\/LEGISLATION\/SUBORDINATE\/2021\/2021-0072\/2021-0072_SL 72 of 2021.pdf","storage_path":"\/Users\/q\/kyleg-data\/working\/SUBORDINATE\/2021\/2021-0072\/2021-0072_SL 72 of 2021.pdf","content_md5":"474bb35c7a217ed41213b42bd5d97946","byte_size":"761168","http_last_modified":null,"fetched_at":"2026-06-16 04:01:10.692772+00"}],"paragraph_count":11,"latest_history":null},"quality":{"expr_id":"1307","doc_id":"1307","quality_state":"needs_review","quality_score":"76","needs_human_review":"t","deterministic_categories":"{duplicate_text,page_header_footer_noise}","llm_categories":"{}","repair_actions":"{collapse_duplicate_text,strip_page_furniture}","finding_severity_counts":"{\"medium\": 2}","finding_summary":"repeated line furniture detected: cayman islands x3; public health act x3; 2021 revision x3; duplicate-line ratio is 14.11%","assessed_at":"2026-06-22 15:29:45.499155+00","updated_at":"2026-06-22 15:29:45.499155+00"}}